Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00455403 · ClinicalTrials.gov registry record · NA
Atheroma Reduction With Chloroquine in Patients With the Metabolic Syndrome (ARCH-MS)
A NA study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- NA
- Development phase
- 357
- Enrollment target
NCT00455403: Completed NA study, sponsored by Washington University School of Medicine.
NCT00455403 is a NA study that has completed, run by Washington University School of Medicine. The registered enrollment target is 357 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00455403, a NA study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 357 participants
- Enrollment target
Study Summary
Metabolic syndrome consists of a group of co-occuring conditions that increase an individual's risk of developing heart disease, stroke, and diabetes. The purpose of this study is to evaluate the long-term effectiveness of chloroquine, a protein-activation medication, at reducing the progression of atherosclerosis in patients with the metabolic syndrome. Sub-study: Vascular endothelial growth factor(VEGF)and Cardiometabolic Risk, The purpose is to determine if the association of VEGF with atherosclerosis indicates that it should be a marker of the disorder.
Primary Outcome
A noninvasive predictor of cardiovascular events, Carotid artery intima-media thickness (CIMT) was measured from B-mode images by a single sonographer using standard approaches
Interventions
- DRUG Placebo Comparator
- DRUG Chloroquine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 357 participants |
| Start Date | 2006-04 |
| Est. Completion | 2009-12 |
| Phase | NA |
What the finished NCT00455403 record still lists
NCT00455403 is an interventional study that assigns participants to a tested intervention. The registered 357 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (75% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo Comparator is the first listed.
NCT00455403 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00455403 about?
NCT00455403 is a clinical study titled "Atheroma Reduction With Chloroquine in Patients With the Metabolic Syndrome (ARCH-MS)". Metabolic syndrome consists of a group of co-occuring conditions that increase an individual's risk of developing heart disease, stroke, and diabetes. The purpose of this study is to evaluate the long-term effectiveness of chloroquine, a protein-activation medication, at reducing the progression of ...
What is the current status of trial NCT00455403?
This trial is currently completed. It is a NA study. The enrollment target is 357 participants. The study started on 2006-04. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00455403?
The interventions under investigation include: Placebo Comparator (DRUG), Chloroquine (DRUG).
Who is sponsoring clinical trial NCT00455403?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00455403's enrollment target sits among peer trials
357 289th of 2000 higher than 1,710 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06062888 · 357 participants · Phase 2
FFP In Traumatic BRAin INjury (FIT-BRAIN) Trial
- NCT06109766 · 357 participants · NA
Delivering Evidence-Based Parenting Services to Families in Child Welfare Using Telehealth
- NCT06231342 · 357 participants · NA
Endotracheal Tube (ETT) 180: Stylet-loaded Endotracheal Tube Rotation Before Insertion
- NCT06533826 · 357 participants · Phase 2
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia